Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc. jointly announced that the European Commission (EC) has granted European market authorization...
The CHMP has recommended granting marketing authorisation for Revestive (teduglutide), from Nycomed, as a once-daily treatment for adult patients with...
Shire has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive...
Shire plc and NPS Pharmaceuticals, Inc. announced that the companies have entered into a merger agreement pursuant to which Shire...
Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.
Gattex/Revestive (teduglutide), from NPS Pharma, offers significant relief for patients with Short-Bowel Syndrome intestinal failure who are reliant on intravenous...
The FDA Gastrointestinal Drugs Advisory Committee voted unanimously to recommend approval of Gattex (teduglutide) from NPS Pharma. It voted 12-0...